<p>Wave Life Sciences Ltd. and GSK continue their research collaboration, focusing on advancing novel oligonucleotide therapies using Wave’s PRISM® platform. In January 2026, GSK selected a fourth program to move forward to development candidate status under their partnership, which allows GSK to advance up to eight programs. Wave is eligible for up to $2.8 billion in milestone and royalty payments as these programs progress. The collaboration spans multiple therapy areas and remains active, with ongoing target validation work and anticipated milestone payments for Wave in 2026 and beyond. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646790) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Reuters

Wave Life Sciences

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

GlaxoSmithKline plc

ALPS Medical Breakthrough

iShares Biotechnology ETF

Bioshares Biotech Clinical Trials Fd

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

SPDR Pharmac

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

iShares US Pharma

Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration